Samita Garg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samita Garg has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Anthony Lembo
2 shared publications- Anthony Lembo
Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA
2 shared publications - Din Hoxha
Division of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA
2 shared publications - Mohannad Dugum
Department of Internal Medicine, Medicine Institute, Cleveland Clinic, Cleveland, Ohio
2 shared publications - Sara Valencia
Department of Gastroenterology, Hepatology and Nutrition, Digestive Disease Institute, Cleveland Clinic, Cleveland, Ohio, USA
2 shared publications Arjun Chatterjee
Internal Medicine Resident, Department of Internal Medicine, Cleveland Clinic, Cleveland, OH
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
The Associations Between Attention-Deficit/Hyperactivity Disorder Stimulant Medications and Irritable Bowel Syndrome
INTRODUCTION: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction affecting 11% of the global population. Patients with attention-deficit/hyperactivity disorder (ADHD) have increased odds of IBS, but this may be confounded by stimulant use. The present study examined the association between ADHD and subsequent IBS, comparing ADHD patients treated with stimulants to those who were unmedicated. METHODS: This retrospective cohort study used the TriNetX U.S. Collaborative Network, a multi-institutional electronic health record platform with de-identified data from 117 million patients across 71 U.S. healthcare organizations. Adults with ADHD were divided into those who had ever received stimulants (stimulant cohort) or never received ADHD medications (“control cohort”). The primary outcome was a diagnostic record of IBS any time after the index event. IBS with Constipation (IBS-C), IBS with diarrhea, and mixed IBS were assessed separately. Cohorts were propensity score matched for demographics, comorbidities, and behavioral factors. Odds ratios (OR) with 95% confidence intervals (CI) were calculated. RESULTS: In the stimulant cohort, 2,104 of 112,832 patients (1.9%) received an IBS diagnosis versus 2,333 of 112,506 patients (2.1%) in the control cohort. Stimulant exposure was associated with a 10.3% decreased risk of any IBS (OR, 0.90; 95% CI, 0.85–0.95) and a 14.1% decreased risk for IBS-C (OR, 0.86; 95% CI, 0.74–0.99). DISCUSSION: Stimulant exposure was associated with a decreased risk of IBS and IBS-C. This supports the view among ADHD researchers that stimulants are effective and low-risk treatments. Future studies using longitudinal or prospective data are needed to validate these findings.
- 21 September 2026
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
Open AccessThe Associations Between Attention-Deficit/Hyperactivity Disorder Stimulant Medications and Irritable Bowel Syndrome
INTRODUCTION: Irritable bowel syndrome (IBS) is a disorder of gut-brain interaction affecting 11% of the global population. Patients with attention-deficit/hyperactivity disorder (ADHD) have increased odds of IBS, but this may be confounded by stimulant use. The present study examined the association between ADHD and subsequent IBS, comparing ADHD patients treated with stimulants to those who were unmedicated. METHODS: This retrospective cohort study used the TriNetX U.S. Collaborative Network, a multi-institutional electronic health record platform with de-identified data from 117 million patients across 71 U.S. healthcare organizations. Adults with ADHD were divided into those who had ever received stimulants (stimulant cohort) or never received ADHD medications (“control cohort”). The primary outcome was a diagnostic record of IBS any time after the index event. IBS with Constipation (IBS-C), IBS with diarrhea, and mixed IBS were assessed separately. Cohorts were propensity score matched for demographics, comorbidities, and behavioral factors. Odds ratios (OR) with 95% confidence intervals (CI) were calculated. RESULTS: In the stimulant cohort, 2,104 of 112,832 patients (1.9%) received an IBS diagnosis versus 2,333 of 112,506 patients (2.1%) in the control cohort. Stimulant exposure was associated with a 10.3% decreased risk of any IBS (OR, 0.90; 95% CI, 0.85–0.95) and a 14.1% decreased risk for IBS-C (OR, 0.86; 95% CI, 0.74–0.99). DISCUSSION: Stimulant exposure was associated with a decreased risk of IBS and IBS-C. This supports the view among ADHD researchers that stimulants are effective and low-risk treatments. Future studies using longitudinal or prospective data are needed to validate these findings.
- Open Access
- 28 August 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (11) , e00913
Adenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for managing diabetes and obesity. Although they improve glycemic control, they also delay gastrointestinal motility, potentially leading to inadequate bowel preparation for colonoscopy, which can increase the risk of missed lesions. This study aimed to evaluate the impact of GLP-1RA use on the quality of bowel preparation and on adenomas and sessile serrated polyp (SSP) detection. METHODS: We conducted a retrospective cohort study of outpatient screening and surveillance colonoscopies at a tertiary academic medical center. Adults who used a GLP-1RA within 1 week of their colonoscopy formed the treatment group; patients not on GLP-1RA (nonusers) who never used GLP-1RA served as controls. Propensity score weighting was applied for age, sex, BMI, race, diabetes status, and relevant medications. The subgroup analysis was stratified based on diabetes status and GLP-1RA use. RESULTS: Among 49,987 patients (4,269 GLP-1RA users, 45,718 nonusers), GLP-1RA use was associated with increased odds of inadequate bowel preparation (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.04–1.46). No significant difference in SSP and adenoma detection was observed. In subgroup analysis, GLP-1RA users with diabetes had the highest odds of inadequate preparation (OR 1.88, 95% CI 1.59–2.24) and the lowest odds of SSP detection (OR 0.71, 95% CI 0.57–0.89). DISCUSSION: GLP-1RA use, particularly among patients with diabetes, is associated with higher odds of inadequate bowel preparation and lower SSP detection, whereas adenoma detection was unaffected. Tailored bowel-prep protocols for GLP-1RA users with diabetes should be evaluated prospectively.
- 28 August 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (11) , e00913
Open AccessAdenoma and Sessile Serrated Polyp Detection Rates in Adults Using Glucagon-Like Peptide-1 Receptor Agonists
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly used for managing diabetes and obesity. Although they improve glycemic control, they also delay gastrointestinal motility, potentially leading to inadequate bowel preparation for colonoscopy, which can increase the risk of missed lesions. This study aimed to evaluate the impact of GLP-1RA use on the quality of bowel preparation and on adenomas and sessile serrated polyp (SSP) detection. METHODS: We conducted a retrospective cohort study of outpatient screening and surveillance colonoscopies at a tertiary academic medical center. Adults who used a GLP-1RA within 1 week of their colonoscopy formed the treatment group; patients not on GLP-1RA (nonusers) who never used GLP-1RA served as controls. Propensity score weighting was applied for age, sex, BMI, race, diabetes status, and relevant medications. The subgroup analysis was stratified based on diabetes status and GLP-1RA use. RESULTS: Among 49,987 patients (4,269 GLP-1RA users, 45,718 nonusers), GLP-1RA use was associated with increased odds of inadequate bowel preparation (odds ratio [OR] 1.23, 95% confidence interval [CI] 1.04–1.46). No significant difference in SSP and adenoma detection was observed. In subgroup analysis, GLP-1RA users with diabetes had the highest odds of inadequate preparation (OR 1.88, 95% CI 1.59–2.24) and the lowest odds of SSP detection (OR 0.71, 95% CI 0.57–0.89). DISCUSSION: GLP-1RA use, particularly among patients with diabetes, is associated with higher odds of inadequate bowel preparation and lower SSP detection, whereas adenoma detection was unaffected. Tailored bowel-prep protocols for GLP-1RA users with diabetes should be evaluated prospectively.
- Open Access
- 1 August 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (8) , e01789
Impact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series
This retrospective case series investigates the impact of GLP-1 receptor agonists (GLP-1RAs) on whole-gut gastrointestinal motility using wireless motility capsule testing. We analyzed 10 patients on GLP-1RAs who underwent wireless motility capsule testing for constipation or gastroparesis to assess gastric, small bowel, and colonic transit times. Delayed gastric emptying time was observed in 80% of patients, whereas delayed whole-gut transit time was noted in 44% of patients. The 3 patients on semaglutide (1 mg) had the longest gastric emptying time, delayed whole-gut transit time, and were the only patients with delayed small bowel transit time. Although limited by retrospective observation, our findings are consistent with the effects of GLP-1RAs on gastric motility delay and suggest an impact on whole-gut motility. With the expanding use of GLP-1RAs, these findings underscore the need for prospective studies using emerging motility technologies to further characterize the motility effects both during treatment and after cessation, thereby guiding evidence-based clinical decision-making.
- 1 August 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (8) , e01789
Open AccessImpact of GLP-1 Receptor Agonists on Whole-Gut Gastrointestinal Motility Using Wireless Motility Capsule: A Descriptive Single-Center Case Series
This retrospective case series investigates the impact of GLP-1 receptor agonists (GLP-1RAs) on whole-gut gastrointestinal motility using wireless motility capsule testing. We analyzed 10 patients on GLP-1RAs who underwent wireless motility capsule testing for constipation or gastroparesis to assess gastric, small bowel, and colonic transit times. Delayed gastric emptying time was observed in 80% of patients, whereas delayed whole-gut transit time was noted in 44% of patients. The 3 patients on semaglutide (1 mg) had the longest gastric emptying time, delayed whole-gut transit time, and were the only patients with delayed small bowel transit time. Although limited by retrospective observation, our findings are consistent with the effects of GLP-1RAs on gastric motility delay and suggest an impact on whole-gut motility. With the expanding use of GLP-1RAs, these findings underscore the need for prospective studies using emerging motility technologies to further characterize the motility effects both during treatment and after cessation, thereby guiding evidence-based clinical decision-making.
- Open Access
- 4 July 2025
- Published by Elsevier in Gastro Hep Advances
- Vol. 4 (10)
All-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium–Glucose Cotransporter-2 Inhibitors
- 4 July 2025
- Published by Elsevier in Gastro Hep Advances
- Vol. 4 (10)
Open AccessAll-Cause Mortality and Gastrointestinal Adverse Effects in Adults With Type 2 Diabetes on Glucagon-Like Peptide-1 Receptor Agonists vs Sodium–Glucose Cotransporter-2 Inhibitors
- Open Access
- 8 March 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (6) , 2069-2078
Differences in Gastrointestinal Motility in Adults with Type 1 and Type 2 Diabetes Using Wireless Motility Capsule
Purpose Gastrointestinal motility disorders are common in diabetes, though their prevalence and distribution have not been evaluated. The Wireless Motility Capsule (WMC) assesses transit times and pressures of the entire gastrointestinal (GI) tract in a single study. This study aimed to evaluate the prevalence and patterns of GI transit abnormalities using WMC in patients with diabetes. Methods This retrospective study included adult patients with Type 1 (T1D) and Type 2 Diabetes (T2D) who underwent WMC testing. Whole gut transit time (WGTT), gastric emptying time (GET), small bowel transit time (SBTT) and colon transit time (CTT) were analyzed. Univariate and multivariable analyses identified risk factors for delayed transit. The rates of diabetic complications were assessed. Kaplan–Meier estimates of mortality rates at 1, 3, and 5 years were compared for patients with T1D and T2D. Results A total of 475 patients (mean age of 54.4 years, 74% female) were included. Of these, 25.9% had T1D and 74.1% had T2D. Mean diabetes duration was 11.4 years. Patients with T1D had a higher mean disease duration of 21.7 years and those with T2D of 7.7 years. More than 35% of patients had HbA1c > 8 and 34% of patients had an HgbA1c between 6.5 and 7.99%. T1D patients had a higher mean HbA1c of 8.6% compared to 7.5% in T2D. Mean BMI was 32.3 in T2D and 26.5 in T1D. Mean BMI was higher in those with normal motility (32.9) than delayed motility (30.1). Delayed transit was observed in 75.8% with delayed GET (58.8%) being the most common abnormality. T2D had shorter median GET (4.4) than T1D (6.1) and longer CTT (95.9) than T1D (79.3). SBTT had an inverse correlation with HbA1c (-0.16). Microvascular complications were greater in T1D including neuropathy in 64.2%, retinopathy in 35% and nephropathy in 31.7% compared to T2D which were: neuropathy 50.3%, retinopathy 11.1% and nephropathy 19%. 7.3 and 1.1% of patients with T1D and T2D had kidney or pancreas transplants respectively. Kaplan–Meier analysis showed no significant difference in mortality in T1D vs T2D. Conclusion This study reports the prevalence of GI motility abnormalities in patients with longer duration of diabetes, higher HbA1c, lower BMI and associated diabetes microvascular complications. Delayed gastric emptying was the most common finding with greater prevalence of GET delay in T1D vs. T2D. T2D had shorter GET but longer CTT. Mean diabetes duration was 11.4 years and > 70% of patients with diabetes had suboptimal glucose control. Microvascular complications and pancreas/kidney transplant were higher in patients with T1D. Mortality rates were not different in T1D vs T2D. Identifying GI motility disorders in diabetes can guide management to improve outcomes.
- 8 March 2025
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 70 (6) , 2069-2078
Open AccessDifferences in Gastrointestinal Motility in Adults with Type 1 and Type 2 Diabetes Using Wireless Motility Capsule
Purpose Gastrointestinal motility disorders are common in diabetes, though their prevalence and distribution have not been evaluated. The Wireless Motility Capsule (WMC) assesses transit times and pressures of the entire gastrointestinal (GI) tract in a single study. This study aimed to evaluate the prevalence and patterns of GI transit abnormalities using WMC in patients with diabetes. Methods This retrospective study included adult patients with Type 1 (T1D) and Type 2 Diabetes (T2D) who underwent WMC testing. Whole gut transit time (WGTT), gastric emptying time (GET), small bowel transit time (SBTT) and colon transit time (CTT) were analyzed. Univariate and multivariable analyses identified risk factors for delayed transit. The rates of diabetic complications were assessed. Kaplan–Meier estimates of mortality rates at 1, 3, and 5 years were compared for patients with T1D and T2D. Results A total of 475 patients (mean age of 54.4 years, 74% female) were included. Of these, 25.9% had T1D and 74.1% had T2D. Mean diabetes duration was 11.4 years. Patients with T1D had a higher mean disease duration of 21.7 years and those with T2D of 7.7 years. More than 35% of patients had HbA1c > 8 and 34% of patients had an HgbA1c between 6.5 and 7.99%. T1D patients had a higher mean HbA1c of 8.6% compared to 7.5% in T2D. Mean BMI was 32.3 in T2D and 26.5 in T1D. Mean BMI was higher in those with normal motility (32.9) than delayed motility (30.1). Delayed transit was observed in 75.8% with delayed GET (58.8%) being the most common abnormality. T2D had shorter median GET (4.4) than T1D (6.1) and longer CTT (95.9) than T1D (79.3). SBTT had an inverse correlation with HbA1c (-0.16). Microvascular complications were greater in T1D including neuropathy in 64.2%, retinopathy in 35% and nephropathy in 31.7% compared to T2D which were: neuropathy 50.3%, retinopathy 11.1% and nephropathy 19%. 7.3 and 1.1% of patients with T1D and T2D had kidney or pancreas transplants respectively. Kaplan–Meier analysis showed no significant difference in mortality in T1D vs T2D. Conclusion This study reports the prevalence of GI motility abnormalities in patients with longer duration of diabetes, higher HbA1c, lower BMI and associated diabetes microvascular complications. Delayed gastric emptying was the most common finding with greater prevalence of GET delay in T1D vs. T2D. T2D had shorter GET but longer CTT. Mean diabetes duration was 11.4 years and > 70% of patients with diabetes had suboptimal glucose control. Microvascular complications and pancreas/kidney transplant were higher in patients with T1D. Mortality rates were not different in T1D vs T2D. Identifying GI motility disorders in diabetes can guide management to improve outcomes.
- Open Access
- 3 June 2024
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 91 (6) , 373-383
Gastroparesis for the nongastroenterologist
Gastroparesis is a heterogeneous motility disorder characterized by nausea, vomiting, and postprandial fullness. Its diagnosis requires objective documentation of delayed gastric emptying of solid food and exclusion of mechanical obstruction. Its epidemiology is unclear, and the main causes are diabetes mellitus and idiopathic disease. Cardinal symptoms often co-occur. Management involves nutritional assessment, dietary changes, drug evaluation, glycemic control (for patients with diabetes mellitus), and symptom relief. In this review, we explore challenges nongastroenterologists may encounter and how they can use current recommendations to manage patients with gastroparesis.
- 3 June 2024
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 91 (6) , 373-383
Open AccessGastroparesis for the nongastroenterologist
Gastroparesis is a heterogeneous motility disorder characterized by nausea, vomiting, and postprandial fullness. Its diagnosis requires objective documentation of delayed gastric emptying of solid food and exclusion of mechanical obstruction. Its epidemiology is unclear, and the main causes are diabetes mellitus and idiopathic disease. Cardinal symptoms often co-occur. Management involves nutritional assessment, dietary changes, drug evaluation, glycemic control (for patients with diabetes mellitus), and symptom relief. In this review, we explore challenges nongastroenterologists may encounter and how they can use current recommendations to manage patients with gastroparesis.
- 1 September 2016
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 83 (9) , 655-662
Managing irritable bowel syndrome: The low-FODMAP diet
A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) has been found to significantly reduce symptoms of irritable bowel syndrome (IBS). The diet is best implemented in two phases: initial strict elimination of foods high in FODMAPs, then gradual reintroduction based on symptoms. Further study of this diet's effect on intestinal microbiota is needed.
- 1 September 2016
- Published by Cleveland Clinic Journal of Medicine in Cleveland Clinic Journal of Medicine
- Vol. 83 (9) , 655-662
Managing irritable bowel syndrome: The low-FODMAP diet
A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) has been found to significantly reduce symptoms of irritable bowel syndrome (IBS). The diet is best implemented in two phases: initial strict elimination of foods high in FODMAPs, then gradual reintroduction based on symptoms. Further study of this diet's effect on intestinal microbiota is needed.
- 1 September 2014
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 16 (9) , 547-549
Bariatric Surgery: An Attractive Therapeutic Modality for Type 2 Diabetes Mellitus
- 1 September 2014
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 16 (9) , 547-549
Bariatric Surgery: An Attractive Therapeutic Modality for Type 2 Diabetes Mellitus